
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
over 26 years ago
Discussionover 26 years ago
Bibliographyover 26 years ago
Participating Facultyover 26 years ago
Introduction: Overactive Bladder - Defining the Diseaseover 26 years ago
The Prevalence of Overactive Bladderover 26 years ago
Comorbidities Associated with Overactive Bladderover 26 years ago
Overactive Bladder Significantly Affects Overall Quality of Lifeover 26 years ago
Economic Considerations in Overactive Bladder





